331 related articles for article (PubMed ID: 24336016)
21. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
22. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.
Held C; Asenblad N; Bassand JP; Becker RC; Cannon CP; Claeys MJ; Harrington RA; Horrow J; Husted S; James SK; Mahaffey KW; Nicolau JC; Scirica BM; Storey RF; Vintila M; Ycas J; Wallentin L
J Am Coll Cardiol; 2011 Feb; 57(6):672-84. PubMed ID: 21194870
[TBL] [Abstract][Full Text] [Related]
23. Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
Tang XF; Fan JY; Meng J; Jin C; Yuan JQ; Yang YJ
Atherosclerosis; 2014 Apr; 233(2):568-578. PubMed ID: 24534451
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials.
Mariani M; Mariani G; De Servi S
Expert Rev Cardiovasc Ther; 2009 Jan; 7(1):17-23. PubMed ID: 19105763
[TBL] [Abstract][Full Text] [Related]
25. In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study.
Bagai A; Peterson ED; Honeycutt E; Effron MB; Cohen DJ; Goodman SG; Anstrom KJ; Gupta A; Messenger JC; Wang TY
Eur Heart J Acute Cardiovasc Care; 2015 Dec; 4(6):499-508. PubMed ID: 25515725
[TBL] [Abstract][Full Text] [Related]
26. Meta-Analysis of Potent P2Y12-ADP Receptor Antagonist Therapy Compared to Clopidogrel Therapy in Acute Coronary Syndrome Patients with Chronic Kidney Disease.
Bonello L; Laine M; Lemesle G; Puymirat E; Dabry T; Thuny F; Paganelli F; Aradi D; Frere C; Burtey S; Sibbing D; Mancini J
Thromb Haemost; 2018 Oct; 118(10):1839-1846. PubMed ID: 30235475
[TBL] [Abstract][Full Text] [Related]
27. Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes.
Quinlan DJ; Eikelboom JW; Goodman SG; Welsh RC; Fitchett DH; Théroux P; Mehta SR
Eur Heart J; 2011 Sep; 32(18):2256-65. PubMed ID: 21624900
[TBL] [Abstract][Full Text] [Related]
28. Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus.
Valentine N; Van de Laar FA; van Driel ML
Cochrane Database Syst Rev; 2012 Nov; 11():CD005449. PubMed ID: 23152231
[TBL] [Abstract][Full Text] [Related]
29. Ticagrelor: oral reversible P2Y(12) receptor antagonist for the management of acute coronary syndromes.
Cheng JW
Clin Ther; 2012 Jun; 34(6):1209-20. PubMed ID: 22521881
[TBL] [Abstract][Full Text] [Related]
30. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Motovska Z; Kala P
Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
[TBL] [Abstract][Full Text] [Related]
31. Comparative Efficacy and Safety of Oral P2Y
Navarese EP; Khan SU; Kołodziejczak M; Kubica J; Buccheri S; Cannon CP; Gurbel PA; De Servi S; Budaj A; Bartorelli A; Trabattoni D; Ohman EM; Wallentin L; Roe MT; James S
Circulation; 2020 Jul; 142(2):150-160. PubMed ID: 32468837
[TBL] [Abstract][Full Text] [Related]
32. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
[TBL] [Abstract][Full Text] [Related]
33. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
[TBL] [Abstract][Full Text] [Related]
34. Lessons from platelet inhibition and patient outcomes.
Held C
Curr Opin Cardiol; 2012 Jul; 27(4):355-60. PubMed ID: 22565140
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of IIb/IIIa inhibitors in combination with highly active oral antiplatelet regimens in acute coronary syndromes: A meta-analysis of pivotal trials.
Roule V; Agueznai M; Sabatier R; Blanchart K; Lemaître A; Ardouin P; Collet JP; Milliez P; Montalescot G; Beygui F
Platelets; 2017 Mar; 28(2):174-181. PubMed ID: 27657930
[TBL] [Abstract][Full Text] [Related]
36. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
Steg PG; Harrington RA; Emanuelsson H; Katus HA; Mahaffey KW; Meier B; Storey RF; Wojdyla DM; Lewis BS; Maurer G; Wallentin L; James SK;
Circulation; 2013 Sep; 128(10):1055-65. PubMed ID: 23900047
[TBL] [Abstract][Full Text] [Related]
37. Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions.
Steiner S; Moertl D; Chen L; Coyle D; Wells GA
Thromb Haemost; 2012 Aug; 108(2):318-27. PubMed ID: 22627948
[TBL] [Abstract][Full Text] [Related]
38. Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview.
Verdoia M; Barbieri L; Suryapranata H; De Luca G
Platelets; 2016; 27(2):93-104. PubMed ID: 25970631
[TBL] [Abstract][Full Text] [Related]
39. Current Evidence on Platelet P2Y12 Receptor Inhibitors: Is There Still a Role for Clopidogrel in 2015?
Qutub MA; Chong AY; So DY
Can J Cardiol; 2015 Dec; 31(12):1481-4. PubMed ID: 26243350
[TBL] [Abstract][Full Text] [Related]
40. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
Roe MT; Armstrong PW; Fox KA; White HD; Prabhakaran D; Goodman SG; Cornel JH; Bhatt DL; Clemmensen P; Martinez F; Ardissino D; Nicolau JC; Boden WE; Gurbel PA; Ruzyllo W; Dalby AJ; McGuire DK; Leiva-Pons JL; Parkhomenko A; Gottlieb S; Topacio GO; Hamm C; Pavlides G; Goudev AR; Oto A; Tseng CD; Merkely B; Gasparovic V; Corbalan R; Cinteză M; McLendon RC; Winters KJ; Brown EB; Lokhnygina Y; Aylward PE; Huber K; Hochman JS; Ohman EM;
N Engl J Med; 2012 Oct; 367(14):1297-309. PubMed ID: 22920930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]